Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer

International Journal of Cancer

Volumn 107, Issue 5, 2003, Pages 854-862

  Ginestier, Christophe ^a   Bardou, Valérie Jeanne ^a   Popovici, Cornel ^a   Charafe Jauffret, Emmanuelle ^a,b   Bertucci, François ^a,b   Geneix, Jeannine ^a   Adélaïde, José ^a   Chaffanet, Max ^a   Hassoun, Jacques ^a,b   Viens, Patrice ^a,b   Jacquemier, Jocelyne ^a   Birnbaum, Daniel ^a,c  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSERM   (France)

Author keywords

Breast cancer; Chromosome 3; FHIT; Prognosis; Tissue microarray

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CHROMOSOME 3; FEMALE; FHIT GENE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ACID ANHYDRIDE HYDROLASES; ADULT; BREAST NEOPLASMS; FEMALE; GENE DELETION; GENES, TUMOR SUPPRESSOR; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 10744220604     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11462     Document Type: Article

References (46)

1. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ Jr, Deshler A, Fulton S, Hendricks CB, Kemeny M, Komblith AB, Louis TA, Markman M, et al. National Institutes of Health consensus development conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001;93:979-89.
2. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. Seventh International Conference on adjuvant therapy of primary breast cancer. J Clin Oncol 2001;19:3817-27.
3. Bertucci F, Viens P, Hingamp P, Nasser V, Houlgatte R, Birnbaum D. Breast cancer revisited using DNA array-based gene expression profiling. Int J Cancer 2003;103:565-71.
4. Bertucci F, Houlgatte R, Benziane A, Granjeaud S, Adelaide J, Tagett R, Loriod B, Jacquemier J, Viens P, Jordan B, Birnbaum D, Nguyen C. Expression profiling in primary breast carcinomas using arrays of candidate genes. Hum Mol Genet 2000;9:2981-91.
5. Bertucci F, Nasser V, Granjeaud S, Eisinger F, Adelaide J, Tagett R, Loriod B, Giaconia A, Benziane A, Devilard E, Jacquemier J, Viens P, et al. Gene expression profiles of poor prognosis primary breast cancer correlate with survival. Hum Mol Genet 2002;11: 863-72.
6. Van't Veer LJ, Dai H, van de Vijver M, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-5.
7. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
8. Minori K, Druck T, Inoue H, Alder H, Berk L, Mori M, Huebner K, Croce C. Cancer-specific chromosome alterations in the constitutive fragile region FRA3B. Proc Natl Acad Sci USA 1999;96: 7456-61.
9. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 2000;60:2140-5.
10. Ried K, Finnis M, Hobson L, Mangelsdorf M, Dayan S, Nancarrow JK, Woollatt E, Kremmidiotis G, Gardner A, Venter D, Baker E, Richards RI. Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum Mol Genet 2000;9:1651-63.
11. Richards RI. Fragile and unstable chromosomes in cancer: cause and consequences. Trends Genet 2001;17:339-345.
12. Brenner C. Hint, Fhit, and GalT: function, structure, evolution, and mechanisms of three branches of the histidine triad superfamily of nucleotide hydrolases and transferases. Biochemistry 2002;41:9003-14.
13. Huebner K, Croce CM. FRA3B and other common fragile sites: the weakest links. Nat Rev Cancer 2001;1:214-21.
14. Ingvarsson S. FHIT alterations in breast cancer. Semin Cancer Biol 2001;11:361-6.
15. Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K, Croce CM. FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol 2002;3:748-64.
16. Fong LYY, Fidanza V, Zanesi N, Lock LF, Siracusa LD, Mancini R, Siprashvili Z, Ottey M, Martin SE, Druck T, McCue PA, Croce CM, Muir-Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci USA 2000;97:4742-7.
17. Zanesi N, Fidanza V, Fong LY, Mancini R, Druck T, Valtieri M, Rudiger T, McCue PA, Croce CM, Huebner K. The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci USA 2001;98:10250-5.
18. Ishii H, Dumon KR, Vecchione A, Fong LY, Baffa R, Huebner K, Croce CM. Potential cancer therapy with the fragile histidine triad gene. JAMA 2001;286:2441-9.
19. Geurts JM, Schoenmakers EF, Roijer E, Stenman G, Van de Ven WJ. Expression of reciprocal hybrid transcripts of HMGIC and FHIT in a pleomorphic adenoma of the parotid gland. Cancer Res 1997;57:13-7.
20. Gemmill RM, West JD, Boldog F, Tanaka N, Robinson LJ, Smith DI, Li F, Drabkin HA. The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. Proc Natl Acad Sci USA 1998;95:9572-7.
21. Fang JM, Arlt MF, Burgess AC, Dagenais SL, Beer DG, Glover TW. Translocation breakpoints in FHIT and FRA3B in both homologs of chromosome 3 in an esophageal adenocarcinoma. Genes Chromosomes Cancer 2001;30:292-8.
22. Popovici C, Basset C, Bertucci F, Orsetti B, Adélaïde J, Mozziconacci MJ, Conte N, Murati A, Ginestier C, Charafe-Jauffret E, Ethier SP, Lafage-Pochitaloff M. Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene. Genes Chromosomes Cancer 2002;35:204-18.
23. Richter J, Wagner U, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Wilber K, et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 2000;157:787-94.
24. Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, Bechlian D, Conte N, Adélaïde J, Toiron Y, Nguyen C, Viens P. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol 2002, 161:1223-33.
25. Kaplan E, Meier P. Non-parametric estimation for incomplete observation. J Am Stat Assoc 1958;53:457-471.
26. Peto R, Peto J. Asymptotically efficient rank invariant test procedures (with discussion). J R Stat Soc A 1972;135:185-207.
27. Clark GM. Interpreting and integrating risk factors for patients with primary breast cancer. J Nat Cancer Soc Monographs 2001:30.
28. Cox DR. Regression models and life table. J R Stat Soc B 1972;34: 187-202.
29. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C, Tornielli S, Sard L, Huebner K, Pierotti MA, Croce CM, Pilotti S. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998;58:5032-7.
30. Man S, Ellis I, Sibbering R, Blamey RW, Brook JD. High levels of allele loss at FHIT and ATM genes in non-comedo ductal carcinoma in situ and Grade I tubular invasive breast cancers. Cancer Res 1996;56:5484-9.
31. Ahmadian M, Wistuba II, Fong KM, Behrens C, Kodagoda DR, Saboorian MH, Shay J, Tomlinson GE, Blum J, Minna JD, Gazdar AF. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res 1997;57:3664-8.
32. Campiglio M, Pekarsky Y, Menard S, Tagliabue E, Pilotti S, Croce CM. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res 1999;59:3866-9.
33. Gatalica Z, Lele SM, Rampy BA, Norris BA. The expression of FHIT protein is related inversely to disease progression in patients with breast carcinoma. Cancer 2000;88:1378-83.
34. Martinez A, Walker RA, Shaw JA, Dearing SJ, Maher ER, Latif F. Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features. Mol Pathol 2001;54:300-6.
35. Ingvarsson S, Sigbjornsdottir BI, Huiping C, Jonasson JG, Agnarsson BA. Alterations of FHIT gene in breast cancer: association with tumor progression and patient survival. Cancer Detect Prevent 2001;25: 292-8.
36. Yang Q, Yoshimura G, Suzuma T, Tamaki T, Umemura T, Nakamura M, Nakamura Y, Wang X, Morí I, Sakurai T, Kakudo K. Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma. Clin Cancer Res 2001;7:3869-73.
37. Krivak TC, McBroom JW, Seidman J, Venzon D, Crothers B, MacKoul PJ, Rose GS, Carlson JW, Birrer MJ. Abnormal fragile histidine triad (FHIT) expression in advanced cervical carcinoma: a poor prognostic factor. Cancer Res 2001;61:4382-5.
38. Zhao P, Lu Y, Hu Y, Zhong M, Li Z, Li X. Loss of fragile histidine trial expression in colorectal carcinoma. Zhonghua Bing Li Xue Za Zhi 2002;31:124-7.
39. Tomizawa Y, Nakajima T, Kohno T, Saito R, Yamaguchi N, Yokota J. Clinico-pathological significance of Fhit protein expression in stage I non-small cell lung carcinoma. Cancer Res 1998;58:5478-83.
40. Capuzzi D, Santoro E, Hauck WW, Kovatich AJ, Rosato FE, Baffa R, Huebner K, McCue PA. Fhit expression in gastric adenocarcinoma: correlation with disease stage and survival. Cancer 2000;88:24-34.
41. Lee JI, Soria JC, Hassan K, Liu D, Liu D, Tang X, El-Naggar A, Hong WK, Mao L. Loss of Fhit expression is a predictor of poor outcome in tongue cancer. Cancer Res 2001;61:837-41.
42. Sevignani C, Calin GA, Cesari R, Sarti M, Ishii H, Yendamuri S, Vecchione A, Trapasso F, Croce CM. Restoration of Fragile Histidine Triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines. Cancer Res 2003;63:1183-7.
43. Dumon KR, Ishii H, Vecchione A, Trapasso F, Baldassarre G, Chakrani F, Druck T, Rosato EF, Williams NN, Baffa R, During MJ, Huebner K, et al. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res 2001;61:4827-36.
44. Chaudhuri AR, Khan IA, Prasad V, Robinson AK, Luduena RF, Barnes LD. The tumor suppressor protein FHIT: a novel interaction with tubulin. J Biol Chem 1999;274:24378-82.
45. Yang Q, Nakamura M, Nakamura Y, Yoshimura G, Suzuma T, Umemura T, Shimizu Y, Mori I, Sakurai T, Kakudo K. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer. Clin Cancer Res 2002;8:2890-3.
46. Zhochbauer-Muller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R, Virmani AK, Milchgrub S, Gazdar AF, Minna JD. 5′CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 2001;61:3581-5.